- Home
- ACRV vs RENE Comparison
ACRV vs RENE Comparison
Compare ACRV & RENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- RENE
- Stock Information
- Founded
- ACRV 2018
- RENE 2021
- Country
- ACRV United States
- RENE United States
- Employees
- ACRV N/A
- RENE N/A
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- RENE Blank Checks
- Sector
- ACRV Health Care
- RENE Finance
- Exchange
- ACRV Nasdaq
- RENE Nasdaq
- Market Cap
- ACRV 170.3M
- RENE 151.4M
- IPO Year
- ACRV 2022
- RENE 2022
- Fundamental
- Price
- ACRV $5.65
- RENE $11.71
- Analyst Decision
- ACRV Strong Buy
- RENE
- Analyst Count
- ACRV 5
- RENE 0
- Target Price
- ACRV $22.40
- RENE N/A
- AVG Volume (30 Days)
- ACRV 50.9K
- RENE 4.1K
- Earning Date
- ACRV 11-13-2024
- RENE 01-01-0001
- Dividend Yield
- ACRV N/A
- RENE N/A
- EPS Growth
- ACRV N/A
- RENE 42.92
- EPS
- ACRV N/A
- RENE 0.43
- Revenue
- ACRV N/A
- RENE N/A
- Revenue This Year
- ACRV N/A
- RENE N/A
- Revenue Next Year
- ACRV N/A
- RENE N/A
- P/E Ratio
- ACRV N/A
- RENE $26.90
- Revenue Growth
- ACRV N/A
- RENE N/A
- 52 Week Low
- ACRV $3.19
- RENE $11.01
- 52 Week High
- ACRV $11.90
- RENE $11.78
- Technical
- Relative Strength Index (RSI)
- ACRV 41.71
- RENE 56.27
- Support Level
- ACRV $5.36
- RENE $11.56
- Resistance Level
- ACRV $6.00
- RENE $11.70
- Average True Range (ATR)
- ACRV 0.52
- RENE 0.02
- MACD
- ACRV -0.01
- RENE -0.00
- Stochastic Oscillator
- ACRV 17.74
- RENE 68.18
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About RENE Cartesian Growth Corporation II
Cartesian Growth Corp II is a blank check company.